Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain.
Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase.
Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.
The analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus.
The report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
One of the emerging trends in the market is the emergence of Interferon -free regimens. Various IFN-free regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause fewer side effects than currently approved therapies.
According to the report, the launch of direct-acting antivirals is one of the major drivers of the market. These are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN. They increase the efficacy of treatment and reduce the duration of therapy.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Disease Overview
07. Market Landscape
08. Key Marketed Drugs for Treatment of Chronic Hepatitis C
09. Market Segmentation by MOA
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
20. Other Reports in this Series
- F. Hoffmann-La Roche
- Gilead Sciences
- Johnson & Johnson
- Vertex Pharmaceuticals
- Achillion Pharmaceuticals
- Bristol-Myers Squibb
- Mitsubishi Tanabe Pharma
For more information visit http://www.researchandmarkets.com/research/n8ttk9/global_hepatitis
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets